- Home
- SLRN
SLRN
ACELYRIN INC.
as 04-22-2025 12:40pm EST
Acelyrin Inc is a late-stage clinical biopharmaceutical company. The clinical biopharma segment researches and develops treatments for diseases with pathology related to excess activation of the immune system. It is focused on providing patients with life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines.
| Founded: | 2020 | Country: | United States |
| Employees: | N/A | City: | AGOURA HILLS |
| Market Cap: | 224.6M | IPO Year: | 2023 |
| Target Price: | $9.60 | AVG Volume (30 days): | 940.4K |
| Analyst Decision: | Hold | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.50 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.84 - $7.25 | Next Earning Date: | 05-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 267.11% | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of ACELYRIN INC. (SLRN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Murugan Amar | SLRN | Chief Legal Officer | Mar 17 '25 | Sell | $2.74 | 3,913 | $10,737.27 | 121,587 | |
| Mpofu Shephard | SLRN | Chief Medical Officer | Mar 17 '25 | Sell | $2.74 | 3,211 | $8,810.98 | 121,789 | |
| Kim Mina | SLRN | Chief Executive Officer | Mar 17 '25 | Sell | $2.74 | 17,986 | $49,353.58 | 671,753 |
Latest ACELYRIN INC. News
SLRN Breaking Stock News: Dive into SLRN Ticker-Specific Updates for Smart Investing
MT Newswires
a day ago
Alumis Raises Share Consideration for Acelyrin Acquisition
GlobeNewswire
a day ago
Alumis and ACELYRIN Announce Amended Merger Agreement
GlobeNewswire
18 days ago
Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger
Insider Monkey
a month ago
Acelyrin, Inc. (SLRN): One of the Best Short-Term Stocks to Buy Right Now
BioPharma Dive
a month ago
Makary advances to full senate vote; Acelyrin, Pliant adopt ‘poison pills’
MT Newswires
a month ago
Acelyrin Adopts Stockholder Rights Plan; Shares Up Pre-Bell
GlobeNewswire
a month ago
ACELYRIN Adopts Limited-Duration Stockholder Rights Plan
Simply Wall St.
a month ago
3 Promising Penny Stocks With Over $100M Market Cap
Compare SLRN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SLRN ACELYRIN INC. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.